Clinical Trials
11 trialsNCT02389309 2026-03-09
Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT02238496 2023-05-25
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
Columbia University
Phase 1 Completed
NCT01051557 2021-07-19
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00329719 2018-10-16
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00335764 2018-07-02
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00022724 2018-06-26
CCI-779 in Treating Patients With Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00784914 2018-04-17
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
City of Hope Medical Center
Phase 1 Completed
NCT00112736 2015-06-15
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00949026 2013-11-21
Assessment of Systemically Administered Torisel Delivery to Brain Tumors by Intratumoral Microdialysis
Emory University
Phase 1 Withdrawn
NCT00016328 2013-07-18
CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003712 2012-08-09
CCI-779 in Treating Patients With Advanced Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 1 Completed